Trial Profile
A study evaluating effect of belimumab therapy on T- and B-cell phenotype in a cohort of patients with systemic lupus erythematosus
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Jun 2019
Price :
$35
*
At a glance
- Drugs Belimumab (Primary)
- Indications Systemic lupus erythematosus
- Focus Pharmacodynamics
- 15 Jun 2019 Results presented at the 20th Annual Congress of the European League Against Rheumatism
- 07 Jul 2017 New trial record
- 17 Jun 2017 Results presented at the 18th Annual Congress of the European League Against Rheumatism